CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis and Neurotoxicity Research

Executive Summary: CA-074 is a potent, selective cathepsin B inhibitor (Ki 2–5 nM) with negligible action on cathepsins H and L (Ki ≥40 µM) and minimal cytotoxicity at 10 mM in cell culture [product]. Cathepsin B is a key cysteine protease implicated in necroptosis, cancer metastasis, and neurotoxicity; its inhibition reduces bone metastasis in breast cancer models and suppresses neurotoxic cascades in microglia [Liu et al., 2024]. CA-074 blocks lysosomal membrane permeabilization (LMP)-driven release of cathepsin B, a critical event in MLKL-mediated necroptosis [DOI]. The compound is highly soluble (>19 mg/mL in DMSO) and stable at -20°C, with validated use in both cell culture and in vivo mouse models [APExBIO]. CA-074 enables precise control of proteolytic cascades for mechanistic and translational studies in oncology, immunology, and neuroscience [internal].

Biological Rationale

Cathepsin B (CTSB) is a lysosomal cysteine protease. It plays essential roles in protein catabolism, cell death, and tissue remodeling. Dysregulated cathepsin B activity is implicated in diverse pathological processes, including tumor invasion and metastasis, neurodegeneration, and regulated cell death (necroptosis) [Liu et al., 2024]. In necroptosis, MLKL polymerization induces lysosomal membrane permeabilization (LMP), releasing cathepsin B into the cytosol where it cleaves essential proteins and triggers cell death. In cancer, extracellular cathepsin B degrades extracellular matrix (ECM) components, facilitating tumor dissemination and bone metastasis [internal]. Cathepsin B also modulates immune cell function, influencing helper T cell differentiation and antibody class-switching. Thus, selective cathepsin B inhibition is a precise strategy for dissecting these proteolytic pathways in disease models.

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a small-molecule inhibitor with a molecular weight of 383.44 g/mol and the chemical name (2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid [APExBIO]. It binds irreversibly to the active site cysteine of cathepsin B, resulting in nanomolar inhibition (Ki 2–5 nM) and effectively blocks its proteolytic activity. Selectivity for cathepsin B over cathepsins H and L is high (Ki ≥40–200 µM), minimizing off-target effects [internal]. By inhibiting cathepsin B, CA-074 prevents downstream proteolytic cascades involved in ECM degradation, necroptotic cell death, and immune modulation. In the context of MLKL-driven necroptosis, CA-074 blocks LMP-induced cathepsin B release, protecting cells from non-apoptotic death [DOI]. The compound is highly soluble in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), and water (>5.91 mg/mL with ultrasonic assistance), facilitating diverse experimental workflows.

Evidence & Benchmarks

• CA-074 displays potent inhibition of cathepsin B in vitro with a Ki of 2–5 nM, whereas Ki values for cathepsins H and L are ≥40 µM, confirming high selectivity (APExBIO).
• Chemical inhibition of cathepsin B by CA-074 protects cells from MLKL-mediated necroptosis in human HT-29 colon cancer cells (Liu et al., 2024).
• In a 4T1.2 breast cancer mouse model, CA-074 (50 mg/kg, intraperitoneal) reduces bone metastasis without impacting primary tumor volume (APExBIO).
• CA-074 suppresses neurotoxic effects elicited by Abeta42-activated microglia in neural cell cultures (internal).
• Immune modulation: CA-074 shifts helper T cell activity from Th-2 to Th-1, reducing IgE and IgG1 production in vitro (APExBIO).
• Negligible cytotoxicity observed at 10 mM in cell culture (APExBIO).

This article extends the mechanistic depth explored in Redefining Translational Research: Cathepsin B Inhibition by integrating the latest evidence on MLKL-mediated LMP and necroptosis, providing updated context for CA-074 application. For a detailed discussion of competitive selectivity data, see Harnessing Cathepsin B Inhibition: Strategic Insights, whereas this article clarifies in vivo efficacy and workflow integration.

Applications, Limits & Misconceptions

CA-074 is extensively used in oncology, neuroscience, and immunology research. Applications include:

• Dissecting cathepsin B-mediated proteolytic pathways in cancer metastasis models.
• Elucidating the role of cathepsin B in MLKL-dependent necroptosis and lysosomal membrane permeabilization (Liu et al., 2024).
• Investigating neurotoxicity mechanisms via microglial activation and Abeta42 toxicity.
• Modulating immune cell differentiation, particularly Th-2 to Th-1 switching.

Common Pitfalls or Misconceptions

• CA-074 is not a pan-cathepsin inhibitor; it shows poor inhibition of cathepsins H and L (Ki ≥40 µM).
• It is not suitable for chronic dosing in vivo due to limited stability of prepared solutions; fresh solutions are recommended for each use (APExBIO).
• CA-074 does not inhibit non-cysteine proteases (e.g., cathepsin D, a serine protease).
• Inhibition is irreversible; downstream effects are not rapidly reversible upon washout.
• Does not impact primary tumor proliferation in breast cancer models; the main effect is on metastasis.

Workflow Integration & Parameters

APExBIO supplies CA-074 (SKU: A1926) as a lyophilized solid. Recommended storage is at -20°C. Solubility is >19.17 mg/mL in DMSO, >31.3 mg/mL in ethanol, and >5.91 mg/mL in water with sonication. For cellular assays, CA-074 is non-cytotoxic at up to 10 mM. In vivo, mouse studies use 50 mg/kg intraperitoneally to achieve robust inhibition in metastatic models. Solution stability is limited; prepare fresh aliquots for each experiment. For detailed experimental design guidance, see CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis, which focuses on selectivity and application in advanced workflows. This article further clarifies solution handling and in vivo dosing best practices.

Conclusion & Outlook

CA-074 remains the gold standard for selective cathepsin B inhibition in cancer, neurotoxicity, and immune modulation research. Its nanomolar affinity, robust selectivity, and low cytotoxicity enable precise dissection of cathepsin B-mediated processes. CA-074 is central to translational studies targeting MLKL-mediated necroptosis and LMP-driven cell death. The integration of CA-074 from APExBIO in experimental workflows supports both mechanistic exploration and preclinical validation. Ongoing research will clarify its potential in combination therapies and disease biomarker discovery.

For product specifications and ordering, see CA-074, Cathepsin B inhibitor (A1926 kit, APExBIO).